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Abstract 
Purpose: To prepare and characterize a formulation containing an ethanol extract of Camellia 
ptilophylla leaves (cocoa tea), with a focus on antihyperlipidemic and anti-obesity activities. 
Methods: An aloe vera–based formulation of an ethanol extract of cocoa tea (C. ptilophylla) was 
prepared. The formulation was given orally at 400 mg/kg daily to obese (high-fat diet–induced) mice for 
1 month, and body weight as well as total cholesterol, triglyceride, HDL cholesterol, LDL cholesterol, 
and VLDL cholesterol levels were determined and compared with those of control and standard groups 
(the latter mice received atorvastatin at 400 mg/kg daily). 
Results: At the end of treatment, the standard group exhibited 64.65 % reduction in body weight gain 
and the test group exhibited 48.87 % reduction, compared with control. The group that received the 
formulation had significantly lower levels of serum total cholesterol, triglycerides, and LDL cholesterol, 
and a higher level of HDL cholesterol. 
Conclusion: The formulation of an ethanolic extract of cocoa tea leaves seems to exert 
antihyperlipidemic and anti-obesity activities comparable to those of a modern lipid-lowering agent 
(atorvastatin) in mice. Thus, this natural remedy has the potential to prevent or delay hyperlipidemia and 
the cardiovascular complications associated with diet-induced obesity. 
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Obesity is one of the most common global health 
problems. The condition is associated with 
abnormal levels of blood lipids (hyperlipidemia) 
and lipoproteins (hyperlipoproteinemia). 
Hyperlipidemia comprises a heterogeneous 
group of disorders, characterized by high blood 
levels of one or more lipids and/or lipoproteins 
[atherogenic free fatty acids, triglycerides (TGs; 
hypertriglyceridemia), small dense low-density 
lipoprotein cholesterol (LDL-C; hypercholeste-
rolemia), and apolipoprotein B] and/or low levels 
of anti-atherogenic high- density lipoprotein 
cholesterol (HDL-C) [1]. According to the 
American Association of Clinical Endocrinologists 
and the International Diabetes Federation, 
metabolic syndrome can be defined as a group 
of complex symptoms featuring central obesity 
(waist circumference > 102 cm in males and 
>88 cm in females) and two or more of the 
following: elevated serum level of TGs, elevated 
serum level of glucose (hyperglycemia), elevated 
blood pressure, and reduced serum level of HDL-
associated cholesterol [2]. 
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Obese individuals are at high risk for the 
development or worsening of cardiovascular 
disorders and diabetes [2]. Therefore, dietary 
supplements containing antioxidants and 
hypolipidemic agents may be useful to prevent 
and manage obesity and related complications 
[3,4]. Weight-loss drugs are frequently 
associated with one or more side effects, which 
are sometimes very harmful. Herbal drugs and 
products used in traditional Chinese medicine 
(TCM) have been reported to control and 
manage hyperlipidemia and weight [5]. Over the 
last few decades, hundreds of Chinese herbal 
medicines and other herbal products of various 
forms have been reported to be excellent 
alternatives when used to develop safer and 
more effective anti-obesity drugs. More than 
50 TCM formulae (patented drugs) approved by 
the China Food and Drug Administration are 
used to treat hyperlipidemia [6]. Cocoa tea 
(Camellia ptilophylla) is a natural (caffeine-free) 
plant used for centuries by inhabitants of the 
Longmen area of Guangdong Province, China. 
Research on the therapeutic effects of the plant 
commenced in the 1980s [7,8]. Various studies 
have found that cocoa tea exerts profound 
cytotoxic effects on various cancer cell lines and 
significantly reduces plasma TG levels in 
hyperlipidemic mice [9,10]. 
 
Lipid profile management is one of the most 
successful strategies for the management of 
obesity [11]. The present investigation involved 
the preparation and evaluation of a formulation of 
an ethanolic extract of cocoa tea leaves, with a 







Cocoa tea leaves were collected from the 
Guangdong Academy of Agricultural Sciences, 
China. All other ingredients used were of 
analytical grade. 
 
Preparation and formulation of an ethanol 
leaf extract of cocoa tea 
 
Leaves were dried in the shade, coarsely 
powdered, extracted with n-hexane, and dried for 
5 days in the shade at room temperature. The 
dried residue was immersed in ethanol for 10 
days and an ethanol extract was obtained by 
evaporating off the ethanol in a rotary vacuum 
evaporator (an ice-trap model). The extract was 
vacuum dried and stored in a desiccator. The 
yield was 75.89 % of the original weight of the 
leaves. The extract was dissolved to 20 % w/w, 
with continuous stirring, in the juice of leaves of 
aloe vera. This juice was prepared from the pulp 
of fresh leaves by making longitudinal incisions in 
the mid-surfaces of leaves and then collecting 
the pulp, to which ascorbic acid (0.5 % w/v) was 
added as a stabilizer, with continuous stirring. 
The formulation thus obtained was the 
antihyperlipidemic preparation. 
 
In vivo assessment of antihyperlipidemic and 
anti-obesity activities 
 
Healthy young Swiss albino mice weighing 75 – 
105 g were used. The study protocols were 
approved by the Animal Experimentation Ethics 
Committee, Zhengzhou Cardiovascular Hospital, 
Zhengzhou (approval no. 2014/193). Mice were 
kept in individual polypropylene cages with food 
and water provided ad libitum at 22 ± 2 °C and a 
relative humidity of 50 ± 15 %, under a 12/12-h 
light/dark cycle. The animals were handled as 
recommended by the Guidelines of the European 
Commission [12]. 
 
The mice were divided into four groups of six 
animals each and acclimatized for 1 week prior 
to dosing. Group I (normal control) consumed a 
normal chow diet containing 6 % w/w fat (diet 
SF04-057; Specialty Foods, Glen Forest, 
Western Australia). Hyperlipidemia was induced 
in all other groups by feeding a high-fat diet 
(HFD) containing 21 % w/w butterfat and 0.15 % 
cholesterol (diet SF00-219; Specialty Foods) for 
1 month before the study. The mice were dosed 
as follows. Group I (normal control) mice 
continued on a normal diet. The other groups 
continued on the HFD. Group II (obese control) 
mice received no treatment. Group III (standard 
group) received daily atorvastatin (40 mg/kg, 
orally). Group IV (test group) received the test 
formulation daily (400 mg/kg, orally). 
 
Four weeks later, blood was collected by cardiac 
puncture and various biochemical tests were 
performed [11]. Blood was collected into heparin-
containing tubes and plasma was separated by 
centrifugation (3,000 rpm, 10 min). Lipid levels 
were measured immediately or the plasma was 
frozen (−80 °C) for future use. We measured the 
levels of total cholesterol (TC), TGs, HDL-C, 
creatinine, potassium, LDL-C, and very-low-
density–lipoprotein cholesterol (VLDL-C) using 
the following formulae: LDL-C = TC – HDL-C – 




Results are expressed as means ± standard 
deviations. Statistical analysis was performed 
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using one-way analysis of variance with 
GraphPad Prism© 4.0 software. P < 0.05 was 




Cocoa tea leaf extract was prepared by cold 
infusion, followed by vacuum evaporation of 
ethanol at reduced pressure and low 
temperature. The formulation was given orally to 
obese mice for 4 weeks. Cocoa tea leaves have 
been used traditionally to prepare beverages and 
in TCM in China. We explored the anti-obesity 
and antihyperlipidemic activities of an aloe vera–
based formulation of an ethanolic extract of 
cocoa tea leaves in HFD-induced obese and 
hyperlipidemic mice. 
 
Body weight increased in the HFD group from 
94.09 ± 3.44 to 112.09 ± 2.04 g, and in the 
standard group from 97.09 ± 1.44 g to 107.06 ± 
1.02 g. Body weight increased in mice receiving 
the formulation from 96.08 ± 1.02 g to only 
108.01 ± 2.54 g. At the end of treatment, the 
standard group exhibited a 64.65 % reduction in 
body weight gain, and the test group exhibited a 
48.87 % reduction (by reference to the control), 
compared with the HFD group (Table 1). 
 
It was found that the total lipid profile of the HFD 
group was significantly higher than that of the 
normal control, and those of the HFD + Std. and 
HFD + Test groups were similar to that of the 
normal control. The HFD-induced abnormal lipid 
profile was improved by the herbal formulation. 
The formulation lowered serum TC, TG, and 
LDL-C levels compared with the HFD groups, as 
did the standard drug (Figure 1). 
 
At the end of treatment, the TC concentrations 
were significantly lower in the HFD + Std. (84.88 
± 1.24 mg/dL) and HFD + Test (90.34 ± 1.01 
mg/dL) groups compared with the HFD group 
(201.14 ± 0.09 mg/dL). The TG levels were also 
significantly lower in the HFD + Std. (67.31 ± 
1.02 mg/dL) and HFD + Test (72.66 ± 1.10 
mg/dL) groups compared with the HFD group 
(159.4 ± 0.21 mg/dL). The HDL-C concentrations 
were significantly higher in the HFD + Std. (18.84 
± 0.22 mg/dL) and HFD + Test (16.98 ± 0.12 
mg/dL) groups than in the HFD group (10.98 ± 
0.38 mg/dL). The LDL-C concentrations were 
significantly lower in the HFD + Std. (52.57 ± 
1.84 mg/dL) and HFD + Test (58.83 ± 1.49 
mg/dL) groups than in the HFD group (158.28 ± 
2.44 mg/dL; Table 2). 
 
Table 1: Effect of a formulation of cocoa tea leaf extract on the body weights of obese mice consuming a high-fat 
diet 
 
Body weight Body weight (g) 
Normala HFDa HFD + Testa HFD + Stda 
Initial (g)  90.00 ± 2.09 94.09 ± 3.44 96.08 ± 1.02 97.09 ± 1.44 
Final (g) 95.58 ± 1.11 112.09 ± 2.04 b 108.01 ± 2.54b 107.06 ± 1.02b 
Body weight gain (g) 5.58 ± 1.08 18.00 ± 2.1b 11.93 ± 1.24b 9.97 ± 1.42b 
Increase in body weight vs. 
control (± g) (%)* 
 +12.42 (100%) –6.35 (–48.87%) –4.39 (–64.65%) 
*The increase in body weight gain in the HFD group was taken as 100% and other gains were calculated by 




     Figure 1: Lipid profile of mice with diet-induced obesity 
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Normal 62.0 ± 1.02 59.0 ± 0.14 24.12 ± 0.01 26.08 ± 0.29 11.8 ± 0.01 0.93 ± 0.01 
HFD 201.14 ± 0.09 159.4 ± 0.21 10.98 ± 0.38b 158.28 ±2.44b 31.88 ± 1.11b 0.07 ± 0.12b 
HFD + Std 84.88 ± 1.24 67.31 ± 1.02b 18.84 ± 0.22b 52.57 ± 1.84b 13.46 ± 1.24b 0.36 ± 0.04b 
HFD + Test 90.34 ± 1.01 72.66 ± 1.10b 16.98 ± 0.12b 58.83 ± 1.49b 14.53 ± 0.08b 0.29 ± 0.08b 
aMean ± SD (n = 6); bp < 0.05 
 
HDL/LDL ratio was significantly higher in the 
HFD + Std. (0.36 ± 0.04) and HFD + Test (0.71 ± 
0.21) groups in comparison of HFD group (0.29 ± 
0.08).  Thus, the test formulation showed good 




Various studies have found that high-level 
motivation toward implementing changes in diet 
and lifestyle may not be adequate for body 
weight management in more than 80% of obese 
subjects [13,14]. Therefore, specific drugs are 
necessary. Despite much research effort, only a 
few such drugs are available, and they are 
associated with adverse effects. The United 
States Food and Drug Administration has 
approved certain anti-obesity drugs, but they are 
associated with high incidences of cardiovascular 
and depressive effects. Some such drugs have 
been withdrawn from the market [15]. Because of 
these side effects, natural products are being 
explored as safer alternatives. Crude herbal 
extracts and isolated phytoconstituents can 
induce body weight reduction and prevent diet-
induced obesity [16]. 
 
Our new formulation (and atorvastatin) improved 
the lipid profile by lowering serum TC, TG, and 
LD-C levels compared with the HFD group. 
Various preclinical human studies have 
confirmed the anti-obesity effects of green tea 
extracts [17-19]. The beneficial effects of green 
and cocoa teas have been attributed to 
catechins, particularly epigallocatechin gallate 
(EGCG) [20-23]. Various studies have found that 
cocoa tea supplementation dose-dependently 
downregulated the expression levels of genes 
controlling cholesterol uptake (LDL-R) and 
cholesterol synthesis (HMG Co-A reductase), 
and exhibited strong antioxidant activities [23-
25]. 
 
We conclude that our new formulation improves 
the HDL/LDL ratio, restoring it to the normal 
range. Improved HDL levels contribute to the 
prevention of adiposity. However, further studies 
are required to compare the activities of the 





Short-term treatment with cocoa tea formulation 
effectively reduced the levels of TC, TGs and 
LDL-C, but improved HDL/LDL ratio in diet-
induced obese mice. Thus, the formulation may 
serve as a potential antihyperlipidemic and anti-
obesity agent for the treatment of diet-induced 
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